

## UK DCTN Publication Policy

1. Any publications arising from studies conducted through the Network will be published under 'The International Federation of Dermatology Clinical Trials Networks' followed by the trial name (e.g. 'The International Federation of Dermatology Clinical Trials Networks PATCH Study Group'). In order to comply with the requirements of most publications, the Chief Investigator of the study will be named as the first author eg 'Tony Ormerod and The International Federation of Dermatology Clinical Trials Networks' An appendix detailing the role of each contributor will be included in any publication.
2. The appendix will be grouped according to the role of each contributor and only those individuals who have made a substantial contribution to one or more of the following groups will be listed:
  - **Trial development group and steering group** responsible for the conception and design, or analysis and interpretation of data;
  - **Recruiting group** responsible for patient accrual throughout the study. This includes all principal investigators, co-investors and any other members of the site study teams that have made a significant contribution to recruitment;
  - **Data monitoring committee** responsible for overseeing the study and monitoring adverse event rates;
  - **Writing group** responsible for drafting the article or revising it critically for important intellectual content and final approval of the version to be published;
  - **Other groups** as appropriate for the individual study.
3. The Chief Investigator/Guarantor will be corresponding author.
4. For publications arising from study development conducted through the IFDCTN, the contribution from Network input must be recognised. The appropriate form will depend on the level of contribution made and is to be agreed by the individual study teams. Any such publications should be made available to the IFDCTN co-ordinating centre before submission for publication for revision purposes and final approval.